

Acquired EGFR resistant mutations in Non-Small Cell Lung Cancer (NSCLC).

Luis E. Raez¹, Yasmine Baca², Jorge J. Nieva³, Hirva Mamdani⁴, Gilberto Lopes⁵, Hossein Borghaei⁶, Mark A. Socinski⁷, Chadi Nabhan², Antoinette J. Wozniak⁹, Ari M. Vanderwalde², Carlos Carracedo Uribe¹¹, Hina Khan¹², Stephen V. Liu¹³, Misako Nagasaka¹⁴

Thoracic Oncology Program, Memorial Cancer Institute/Florida Atlantic University, Miami, FL¹; Caris Life Sciences, Phoenix, AZ²; University of Southern California, Norris Cancer Center, Los Angeles, CA³; Barbara Ann Karmanos Cancer Institute, Detroit, MI⁴; University of Miami Miller School of Medicine, Miami, FL⁵; Fox Chase Cancer Center, Philadelphia, PA⁶; AdventHealth Cancer Institute, Orlando, FL⁷; Aptitude Health, Atlanta, GA⁸; Hillman Cancer Center University of Pittsburgh, Pittsburgh, PA⁹; West Cancer Center & Research Institute, Germantown, TN¹⁰; Memorial Healthcare System, Pembroke Pines, FL¹¹; Brown University, Warren Alpert Medical School, Providence, RI¹²; Georgetown University, Department of Hematology and Oncology, School of Medicine, Washington, DC¹³; University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, CA¹⁴

Background:

EGFR mutations are present in more than 10% of patients (pts) with NSCLC in the US. While Figure 2A: Oncoprint for EGFR L718 mutated tumors (N=11) EGFR with tyrosine kinase inhibitors (TKIs) are effective, acquired resistance is expected. Known mechanisms include acquired EGFR mutations (e.g. 718V, c797x, 724s, 721s or T790M); copy number amplifications in MET, ERBB2, and PIK3CA; gene fusion events; and histological transformation. We herein present the prevalence of resistance mutations in the largest reported cohort of EGFR mutant NSCLC.

Methods:

Non-small cell lung cancer (NSCLC) tumor samples were submitted to Caris Life Sciences (Phoenix, AZ) for NextGen Sequencing (NextSeq, 592 Genes) and whole exome sequencing (NovaSeq, WES). PD-L1 expression was tested by IHC using 22c3 (Dako) and TPS scores were reported (cutoff >1). TMB was measured by totaling somatic mutations (TMB-high cutoff > 10 mutations per MB), genomic loss of heterozygosity (gLOH) was determined by WES.





Table 1: Patient demographics

EGFR	Co-occurring				
mutation	T790M	Male	Female	Total	Median age
C797	26	16	22	38	63.5
L718	3	5	6	11	72
G724	1	2	5	7	73
G721	0	2	2	4	61.5
Total	30	25	35	60	65

Results










Figure 3: IO marker prevalence and other co- alterations in EGFR resistance mutants.




Table 2: Summary table of top alterations in acquired EGFR mutated cohort.

EGFR MT	Ν	%	T790M co-mt	PD-L1	TP53	LOH
C797	38	1.2	26/38 (68%)	11/36 (30%)	20/38 (53%)	4/14 (28%)
L718	11	0.3	3/11 (27%)	4/9 (44%)	7/10 (70%)	0/1 (0%)
G724	7	0.2	1/7 (14%)	5/7 (71%)	3/7 (43%)	0/1 (0%)
G721	4	0.1	0/4 (0%)	3/4 (75%)	2/4 (50%)	1/2 (50%)
Total	60			23/56 (41%)	32/59 (54%)	5/18 (28%)

Conclusions

- and G721).
- Additionally, 3/11 co-occured with T790M mutations.
- were PDL1-H and 2% were dMMR/MSI-H.
- patients with resistant EGFR mutant lung cancers.

PRECISION ONCOLOGY ALLIANCE

Of 27,848 NSCLC tumors, 3,223 (12%) had an EGFR sensitizing mutation, 60 (0.2%) had common missense resistance mutations (C797, L718, G724

L718 mutations co-occurred with either L858R (8/11) or exon 19 (3/11).

In the resistance mutant cohort, 13% were TMB-H (>10 Mt/Mb), 41%

Other co-alterations include TP53 (53%), gLOH by WES (28%), CTNNB1 (19%), NFKB1A (13%), APC (10%), PIK3CA (11%) and SMAD4 (9%).

Acquired resistance in EGFR mutant NSCLC is very heterogeneous and their frequency is still low most likely due to lack of enough sequencing of EGFR resistant tumors . These data support the NGS evaluation of